Immunotherapy for head and neck cancer: Present and future

被引：76

作者：

Fasano, Morena ^{[1
]}

Della Corte, Carminia Maria ^{[1
]}

Di Liello, Raimondo ^{[1
]}

Viscardi, Giuseppe ^{[1
]}

Sparano, Francesca ^{[1
]}

Iacovino, Maria Lucia ^{[1
]}

Paragliola, Fernando ^{[1
]}

Piccolo, Antonio ^{[1
]}

Napolitano, Stefania ^{[1
]}

Martini, Giulia ^{[1
]}

Morgillo, Floriana ^{[1
]}

Cappabianca, Salvatore ^{[2
]}

Ciardiello, Fortunato ^{[1
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, I-80131 Naples, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Precis Med, Radiol & Radiotherapy, I-80131 Naples, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 174卷

关键词：

HNSCC; Immunotherapy; ICI; R/M HNSCC; ADCC; Immunotherapy biomarkers; SQUAMOUS-CELL CARCINOMA; RECURRENT/METASTATIC R/M HEAD; PHASE-II TRIAL; METASTATIC HEAD; OPEN-LABEL; INVESTIGATORS CHOICE; HUMAN-PAPILLOMAVIRUS; RANDOMIZED-TRIAL; CHECKMATE; 141; SINGLE-ARM;

D O I：

10.1016/j.critrevonc.2022.103679

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC). Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for different disease settings and many others, alone or in combination, are currently under investigation. Otherwise, as in other cancer types, efficacy, and resistance mechanisms, are not clearly understood. Considering the heterogeneity of the benefit reported in clinical trials, cost-efficacy analysis and the development of an effective patient selection are encouraged. Different pathways involving innate immunity, regulatory T lymphocytes and microbiome are emerging as new potential biomarkers, supported by preclinical and translational data. In this review we report current evidence on immunotherapy in HNC with updates from the main 2021 oncology events as ASCO, AACR and ESMO meetings. We focus on clinical trials results of single agent and combination immunotherapy in different clinical scenario, from (neo)adjuvant to metastatic setting, describing also novel evidence about efficacy and resistance biomarkers.

引用

页数：13

共 107 条

[1] Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy [J].

Albini, Adriana ;

Bruno, Antonino ;

Noonan, Douglas M. ;

Mortara, Lorenzo .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[2]

[Anonymous], 2015, ONCOIMMUNOLOGY, V4

[3] Nivolumab (N) plus ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 [J].

Argiris, A. ;

Harrington, K. ;

Tahara, M. ;

Ferris, R. L. ;

Gillison, M. ;

Fayette, J. ;

Daste, A. ;

Koralewski, P. ;

Nin, R. Mesia ;

Saba, N. F. ;

Mak, M. ;

Avitia, M. A. Alvarez ;

Guminski, A. ;

Muller-Richter, U. ;

Kiyota, N. ;

Roberts, M. ;

Khan, T. A. ;

Miller-Moslin, K. ;

Wei, L. ;

Haddad, R. Robert .

ANNALS OF ONCOLOGY, 2021, 32 :S1310-S1311

[4] Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials [J].

Argiris, A. ;

Li, S. ;

Ghebremichael, M. ;

Egloff, A. M. ;

Wang, L. ;

Forastiere, A. A. ;

Burtness, B. ;

Mehra, R. .

ANNALS OF ONCOLOGY, 2014, 25 (07) :1410-1416

[5] Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma [J].

Atkinson, Victoria ;

Khattak, Adnan ;

Haydon, Andrew ;

Eastgate, Melissa ;

Roy, Amitesh ;

Prithviraj, Prashanth ;

Mueller, Christian ;

Brignone, Chrystelle ;

Triebel, Frederic .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[6] A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease: The PATHWay Study. [J].

Baum, Joshua ;

Karrison, Theodore ;

Yokes, Everett E. ;

Cohen, Roger B. ;

De Souza, Jonas A. ;

Aggarwal, Charu ;

Saloura, Vassiliki ;

Agrawal, Nishant ;

Saba, Nabil F. ;

Langer, Corey J. ;

Seiwert, Tanguy Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[7] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study [J].

Bauml, Joshua ;

Seiwert, Tanguy Y. ;

Pfister, David G. ;

Worden, Francis ;

Liu, Stephen V. ;

Gilbert, Jill ;

Saba, Nabil F. ;

Weiss, Jared ;

Wirth, Lori ;

Sukari, Ammar ;

Kang, Hyunseok ;

Gibson, Michael K. ;

Massarelli, Erminia ;

Powell, Steven ;

Meister, Amy ;

Shu, Xinxin ;

Cheng, Jonathan D. ;

Haddad, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) :1542-+

[8] Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group [J].

Blanchard, P. ;

Landais, C. ;

Petit, C. ;

Zhang, Q. ;

Gregoire, V. ;

Tobias, J. ;

Burtness, B. ;

Ghi, M. G. ;

Janot, F. ;

Overgaard, J. ;

Wolf, G. ;

Lewin, F. ;

Hitt, R. ;

Corvo, R. ;

Budach, V. ;

Trotti, A. ;

Fortpied, C. ;

Hackshaw, A. ;

Bourhis, J. ;

Pignon, J-P. .

ANNALS OF ONCOLOGY, 2016, 27

[9] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[10] Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO) [J].

Bonomo, Pierluigi ;

Desideri, Isacco ;

Loi, Mauro ;

Mangoni, Monica ;

Sottili, Mariangela ;

Marrazzo, Livia ;

Talamonti, Cinzia ;

Greto, Daniela ;

Pallotta, Stefania ;

Livi, Lorenzo .

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2018, 9 :42-47

← 1 2 3 4 5 6 7 8 9 10 →